JeanMarie Guenot is the president and CEO of Amphivena Therapeutics, a subsidiary of Affimed Therapeutics AG. Amphivena was incorporated in 2012. The company has been engaged in manufacture of drugs and treatments for diseases like Hodgkin lymphoma and non-Hodgkin lymphoma. JeanMarie’s deep background in biotechnology and pharmaceutical industry has seen her work with different companies. She is experienced in business development, pharmaceutical R&D, commercial development, corporate, venture capital and project & alliance management.
Before joining Amphivena, Dr. Geunot was managing SKS Ocular. This ophthalmic company incubator specialized in the treatment for glaucoma, dry AMD, delivery technologies of sustained release of ocular drug, ocular inflammation and macular degeneration. She also served as the business adviser for Hoffman-La Roche in Basel and Shanghai. She was VP in charge of corporate & business development at PDL BioPharma where she oversaw mergers and acquisitions, licensing, alliance management and commercial product portfolios. She was among the three candidates present for Phase 2 cancer autoimmune disease drug discussions. She played a major role in the negotiation of Biogen Idec-PDL 50:50 co-development and co-commercialization agreement. The transaction, which amounted to $800 million, included an equity investment of $100 million in PDL. The remaining amount was split between candidates of Biogen Idec/PDL and Hoffman-La Roche.
JeanMarie Guenot approved the ophthalmic indication for the oncology drug to Ophthotech. This is because she is a professional in matters of project, portfolio, and alliance manager in areas of autoimmune diseases, neurology, cardiovascular diseases, oncology and ophthalmic diseases. Her business career premiered at Atlas Venture where she was in charge of venture capital management. She also created life science companies. Guenot is passionate about building and recreating companies. Her career in science started at Hoffman-La Roche where she served as a principal scientist. The company develops drugs for inflammation, autoimmune diseases, metabolic diseases, and oncology.
According to her website, Dr. Guenot pursed her studies at the University of California, San Francisco where she earned her PhD. She is an alumnus of the Wharton School at the University of Pennsylvania where she graduated with her MBA. Her training involved physical and medical chemistry. Guenot focused on semi-empirical methods for molecular dynamics and quantum mechanical, X-ray and NMR refinement, protein structure prediction and drug design. Follow Dr. Guenot further on Facebook.